Real-world postprogression outcomes after first-line treatment with ribociclib plus aromatase inhibitor versus aromatase inhibitor alone in patients with hormone receptor-positive/human epidermal growth factor receptor 2-negative metastatic breast cancer in the United States of America.

Saved in:
Bibliographic Details
Title: Real-world postprogression outcomes after first-line treatment with ribociclib plus aromatase inhibitor versus aromatase inhibitor alone in patients with hormone receptor-positive/human epidermal growth factor receptor 2-negative metastatic breast cancer in the United States of America.
Authors: Hart L; Department of Cancer Medicine, Wake Forest University School of Medicine, Winston-Salem, USA. Electronic address: llhart@flcancer.com., Rugo HS; Department of Medical Oncology & Therapeutics Research, City of Hope Comprehensive Cancer Center, Duarte, USA., Sharma P; Division of Medical Oncology, Department of Internal Medicine, University of Kansas Medical Center, Westwood, USA., Sammons S; Breast Oncology Center, Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, USA., Gadi VK; Division of Hematology and Oncology, Department of Medicine, University of Illinois College of Medicine and University of Illinois Cancer Center, Chicago, USA., Mavros P; KREDHERA, LLC, Hampton, USA., Kaur M; Flatiron Health, New York, USA., Boualam N; Flatiron Health, New York, USA., Keane C; Flatiron Health, New York, USA., Sopher G; Novartis Pharmaceuticals Corporation, East Hanover, USA., Pathak P; Novartis Pharmaceuticals Corporation, East Hanover, USA., Tarantino P; Department of Medicine, Harvard Medical School, Boston, USA.
Source: ESMO open [ESMO Open] 2026 Jul; Vol. 11 (7), pp. 108243. Date of Electronic Publication: 2026 Jul 07.
Publication Type: Journal Article
Journal Info: Publisher: Elsevier Country of Publication: England NLM ID: 101690685 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 2059-7029 (Electronic) Linking ISSN: 20597029 NLM ISO Abbreviation: ESMO Open Subsets: MEDLINE
Database: MEDLINE Ultimate
Description
ISSN:2059-7029
DOI:10.1016/j.esmoop.2026.108243